Abstract
In this article, we review modeling and interpretation of kinetics data obtained from patients with chronic hepatitis B virus infection that has been treated with lamivudine, adefovir dipivoxil, and lamivudine plus famciclovir combination therapy.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / pharmacokinetics
-
Adenine / therapeutic use
-
Antiviral Agents / pharmacokinetics*
-
Antiviral Agents / therapeutic use
-
DNA, Viral / blood
-
DNA, Viral / drug effects*
-
DNA, Viral / genetics
-
Hepatitis B / drug therapy*
-
Hepatitis B / immunology
-
Hepatitis B / virology
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / genetics
-
Hepatitis B virus / physiology*
-
Hepatocytes / drug effects
-
Hepatocytes / virology
-
Lamivudine / pharmacokinetics
-
Lamivudine / therapeutic use
-
Models, Biological
-
Organophosphonates*
-
Reverse Transcriptase Inhibitors / pharmacokinetics
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Viral Load*
-
Virion / physiology
Substances
-
Antiviral Agents
-
DNA, Viral
-
Organophosphonates
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
adefovir
-
Adenine
-
adefovir dipivoxil